Cencora, Inc.
CORNYSEIndustrials · Wholesale-Drugs, Proprietaries & Druggists' Sundries · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B | $189.89B |
| Operating income | $2.63B | $2.18B | $2.34B | $2.37B | $2.35B | −$5.14B |
| Net income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B | −$3.41B |
| Total assets | $76.59B | $67.10B | $62.56B | $56.56B | $57.34B | $44.27B |
| Total liabilities | — | — | — | — | — | — |
| Equity | $1.51B | $645.9M | $522.0M | −$211.6M | $223.4M | −$1.02B |
| EPS (diluted) | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 | $-16.65 |
| Shares out. | 194.0M | 193.3M | 200.7M | 205.7M | 208.1M | 204.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 0.8%
- Net margin
- 0.5%
- Return on equity
- 103.1%
- Return on assets
- 2.0%
- Return on capital (ROCE)
- 14.0%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $7.77
- Revenue growth (YoY)
- 9.3%
- Net income growth (YoY)
- 3.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −3.0%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 good- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Walgreens Boots Alliance, Inc.Activist (13D)Jun 9, 2025
- Blackrock, Inc.Passive (13G)Jan 31, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Durcan Dermot MarkDirector | May 28, 2026 | Buy | 4,000 | $266.26 |
| Tyler Lauren MDirector | May 1, 2026 | Grant | 99 | $304.00 |
| Cooper EllenDirector | May 1, 2026 | Grant | 99 | $304.00 |
| Nally Dennis MDirector | May 1, 2026 | Grant | 116 | $304.00 |
| Battaglia SilvanaOfficer — Executive Vice President | Mar 11, 2026 | Option exercise | 8,415 | $0.00 |
| Campbell Elizabeth SOfficer — Executive Vice President | Mar 11, 2026 | Option exercise | 12,623 | $0.00 |
| Cleary James FOfficer — Chief Financial Officer | Mar 11, 2026 | Option exercise | 12,623 | $0.00 |
| Cooper EllenDirector | Jan 30, 2026 | Grant | 69 | $359.22 |
| Nally Dennis MDirector | Jan 30, 2026 | Grant | 98 | $359.22 |
| Tyler Lauren MDirector | Jan 30, 2026 | Grant | 84 | $359.22 |
| Baumann WernerDirector | Mar 5, 2026 | Grant | 557 | $359.28 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.3M | 1.8 | +1.9% |
| Apr 30, 2026 | 5.2M | 3.5 | +7.3% |
| Apr 15, 2026 | 4.8M | 4.1 | -6.1% |
| Mar 31, 2026 | 5.2M | 2.7 | +4.9% |
| Mar 13, 2026 | 4.9M | 4.7 | +3.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Regulation FD disclosureMay 29, 2026
- Results of operations · Regulation FD disclosureMay 6, 2026
- Regulation FD disclosureMar 23, 2026
- Director / officer change · Regulation FD disclosureMar 17, 2026
- Shareholder voteMar 6, 2026
- Regulation FD disclosure · Other material eventFeb 18, 2026
- Entered a material agreement · New financial obligation · Regulation FD disclosure · Other material eventFeb 13, 2026
- Regulation FD disclosure · Other material eventFeb 11, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KMay 29, 2026
- SDMay 29, 2026
- 4FORM 4May 28, 2026
- 10-QMay 6, 2026
- 8-KMay 6, 2026
- 4FORM 4May 5, 2026
- 4FORM 4May 5, 2026
- 4FORM 4May 5, 2026
- SCHEDULE 13GApr 29, 2026
- 4FORM 4Apr 2, 2026
- SCHEDULE 13G/AMar 26, 2026
- 8-KFORM 8-KMar 23, 2026
- 8-KFORM 8-KMar 17, 2026
- 4FORM 4Mar 13, 2026
- 4FORM 4Mar 13, 2026
Corporate family
Spin-offs from Cencora, Inc. (1)
- PharMerica CORPcompletedMar 26, 2007details
From the spin-off filings we track. Follow a company to walk its own history.